The sugar-reducing drug Yanumet fully demonstrates its effectiveness in internal use. The active ingredients have differences in chemical structure and pharmacological properties from similar insulin preparations, sulfonylureas, amylin, γ-receptor agonists and many others. Etc. By suppressing dipeptidyl peptidase-4, the active component increases the level of incretin hormones that are produced inside the intestine. Usually the amount of such hormones increases due to food intake. Incretinovye substances are considered an element of the internal physiological process of glucose homeostasis.
When the blood sugar level is exceeded or is within normal limits, incretin hormones stimulate active production of insulin. In addition, its release by β-cells in the pancreas is activated, which is explained by the action of control intracellular processes.
Also, the drug Yanumet helps to suppress the excessive release of glucagon. Lowering the glucagon level while increasing the amount of insulin leads to a decrease in the production of glucose in the liver. As a result of such processes, glycemia decreases.
At a low glucose level, the above properties do not appear.
The active components of Yanumet prevent the processes of hydrolysis of incretin hormones with the enzyme dipeptidyl peptidase-4. As a consequence, plasma concentrations of GLP-1 and HIP increase, glucose-dependent insulin production increases and glucagon release is reduced. Metformin reduces the production of glucose and the degree of its absorption in the intestinal cavity, and enhances the susceptibility to insulin by glucose disposal.